Kyle Smith (KS), President and Chief Operating Officer at Aprecia Pharmaceuticals, talks to Dr Kevin Robinson (KSR) about the challenges of scaling up complex medicines, where process control can be improved, how to adopt new technologies without added risk and which approaches will shape the future of pharmaceutical manufacturing.
KSR: As medicines and manufacturing processes become more complex, where are the biggest challenges when moving from development into scalable production?
KS: Looking back at the conversations and developments at CPHI, one of the biggest challenges facing the industry is balancing rapid development timelines with the flexibility needed to support evolving clinical programmes.
As molecules become more complex, sponsors often need to adjust dosage strengths, forms or formulations as clinical data emerge, creating pressure to move quickly without disrupting development.
Another key challenge is ensuring a smooth transition from development to commercial production.
Manufacturing processes and products that work well on a small scale do not always transfer directly to large volumes, sometimes requiring formulation/process changes during scale-up.
